Good MorningEquity markets tried to build on the previous week's strength, but the gains were fleeting. The S&P 500 closed with a small daily gain but aligned with recent highs. The move suggests a lack of momentum and increasing resistance to higher prices that may cap gains for the remainder of the summer. The CPI report was good but aligned with the outlook for FOMC rate cuts that are already priced into the market. There is a high risk that it will be a sell-the-news event, and a stock market price correction will soon follow.
The S&P 500 may not fall far. The outlook for earnings growth remains robust, and with interest rates set to drop, strength will bleed into a broader array of sectors. In this scenario, a market correction is a buy-the-dip opportunity leading to another multi-quarter rally for the index. Featured: The suits might come after me for showing you this (Ad) 
|
Auto/Tires/Trucks | |
Solid-state battery technology company QuantumScape Co. (NYSE: QS) stock awakened, jumping nearly 46% on news of a new agreement with PowerCo, a subsidiary of Volkswagen AG (OTCMKTS: VWAGY). QuantumScape received much hype and fanfare in 2021 regarding its solid-state lithium-metal battery techn... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Technology | |
NVIDIA Corp. (NASDAQ: NVDA) continues to be one of the best-performing stocks in 2024. At a split-adjusted price of $129.71, NVDA stock is up 160% in 2024. However, NVIDIA’s coattails appear to be fairly short. The market growth is limited to a relatively narrow range of stocks, mostly in la... Read the Full Story |
|
Auto/Tires/Trucks | |
Ford Motor Company (NYSE: F) is navigating a significant transformation as the automotive sector transitions from gas power and embraces the electric vehicle (EV) future. This shift has led many investors and Ford Motor’s analyst community to wonder if now is the time to buy Ford Motor sto... Read the Full Story |
|
From Our Partners | | Roger Scott just unveiled a day-trading tool designed to identify the first wave of institutional buying before a full order moves through the market - potentially in minutes.
On April 14th, the tool flagged early institutional buys on HOOD at 9:45 am, delivering a 24% return in 6 minutes. Minutes later, a signal on MSTR locked in a 33% return in 12 minutes. Free access is available now. | | Secure your free pass to the real-time institutional order tracker today |
|
Transportation | |
The iShares Russell 2000 ETF (NYSE: IWM) experienced a significant breakout above multi-year resistance last week, sparked by the release of the CPI inflation data on Thursday. This move was one of the most eye-opening events of the week, drawing significant attention to small-cap stocks.
IWM's I... Read the Full Story |
|
Markets | |
International Gaming Technology PLC (NYSE: IGT) provides worldwide electronic gambling, gaming, and lottery products and services. It’s well known for providing most of the slot machines in Las Vegas in the pre-pandemic era. The company has expanded to include digital games through its Pla... Read the Full Story |
|
From Our Partners | | Roger Scott spent twenty years on Wall Street moving billions through the market. Now he's exposing the 'empty chair' signal he says sits behind the most stunning stock moves retail investors rarely hear about.
The same signal reportedly triggered a 138% return on WMT in two weeks and a 157% return on Cencora in one week, according to his research. | | Watch Roger Scott reveal the empty chair signal today |
|
Finance | |
The insurance industry is being rattled by fintech disruptors like Lemonade Inc. (NYSE: LMND). Critics will say that underwriting policies are an art form and that human actuaries and adjusters can’t be replaced by artificial intelligence (AI). Insurance policies are best drawn up face-to-... Read the Full Story |
|
Consumer Staples | |
It’s no secret that most of the market’s attention has been centered around the technology sector, especially in stocks dealing with the advancement and global adoption of artificial intelligence, names like NVIDIA Co. (NASDAQ: NVDA) and even Taiwan Semiconductor Manufacturing (NYSE: T... Read the Full Story |
|
Consumer Staples | |
Fabless semiconductor developer Advanced Micro Devices Inc. (NASDAQ: AMD) stock had been largely unresponsive during the artificial intelligence (AI) boom as its shares peaked at $227.30 on March 8, 2024. On the other hand, rival NVIDIA Co. (NASDAQ: NVDA) has taken all the spotlight, hitting all... Read the Full Story |
|
Auto/Tires/Trucks | |
The June CPI was much better than expected and has the broad market set up to rally over the next six to 12 months. The rally is driven by the expectation for FOMC interest rate cuts, which will reduce the cost of money and reinvigorate the bull market, assuming no recession unfolds. While most st... Read the Full Story |
|
Retail/Wholesale | |
As the dominant eCommerce giant, Alibaba Group Holding Ltd. (NYSE: BABA) is often considered the Amazon.com Inc. (NASDAQ: AMZN) of China. By sales, it's the third largest eCommerce giant in the world. With shares trading up just 3.6% year-to-date (YTD), it is also considerably underperforming th... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. | Should I Buy Alnylam Pharmaceuticals Stock? ALNY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Sunday, July 12, 2026 at 6:49 PM.
Alnylam Pharmaceuticals Bull Case -
The company recently reported a significant increase in revenue, with a year-over-year growth of over 96%, indicating strong demand for its products.
-
Alnylam Pharmaceuticals, Inc. achieved earnings per share of $1.99, surpassing analyst expectations, which reflects robust financial performance and potential for future profitability.
-
The current stock price is around $295, which is relatively stable compared to its 1-year high of $495.55, suggesting potential for recovery and growth.
-
With a return on equity of 85.76%, the company demonstrates effective management of shareholder equity, which can attract investors looking for strong returns.
-
The firm has a solid current ratio of 3.13, indicating good short-term financial health and the ability to cover its liabilities, which is reassuring for investors.
Alnylam Pharmaceuticals Bear Case -
The company has a high price-to-earnings ratio of 82.25, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
-
Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.94, indicating that it relies significantly on debt financing, which could pose risks if market conditions change.
-
Insider selling activity has been noted, with several executives reducing their stakes, which may signal a lack of confidence in the company's short-term prospects.
-
The stock has shown volatility, with a beta of 0.29, indicating that it may not be as stable as some investors prefer, which could lead to unpredictable price movements.
-
Despite recent revenue growth, the company previously reported a loss of ($0.44) EPS in the same quarter last year, highlighting potential inconsistencies in performance.
| | View Today's Stock Pick |
|
